Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chaiqin Tonglin
- Lead developer
- Yiling Pharmaceutical
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Chaiqin Tonglin (also known as Chaiqin Tonglin Tablets) is an investigational Category 1.1 traditional Chinese medicine (TCM) being developed by Shijiazhuang Yiling Pharmaceutical. Formulated as an oral tablet, it is a multi-herb preparation designed to clear damp-heat and resolve qi stagnation in the liver meridian and lower jiao. Chaiqin Tonglin is currently in Phase II clinical development in China for the treatment of acute lower urinary tract infections and recurrent urinary tract infections.
- Other names
- Chaiqin Tonglin Tablets柴芩通淋柴芩通淋片
Beyond the preview
Go deeper on Chaiqin Tonglin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chaiqin Tonglin.
Work on Chaiqin Tonglin? Claim this page to correct or add information. Claim this page